Randomized Clinical Trial
Copyright ©The Author(s) 2017.
World J Cardiol. Nov 26, 2017; 9(11): 807-812
Published online Nov 26, 2017. doi: 10.4330/wjc.v9.i11.807
Table 1 Clinical and angiographic profiles of Safeguard Radial vs TR band groups at baseline-total patient cohort
VariablesSafeguard radial, n = 42TR band, n = 42P value
Age, years63.8 ± 10.966.8 ± 10.80.21
Gender, male/female ratio31/1137/50.16
BMI, kg/m229.2 ± 3.929.0 ± 5.70.88
Diabetes4 (10%)8 (19%)0.22
CKD1 (2%)2 (5%)0.56
PAD0%1 (2%)0.32
Indication
Elective18160.88
UA680.9
NSTEMI1380.7
STEMI5100.6
Table 2 Procedural profiles of Safeguard Radial vs TR band groups
VariablesSafeguard radial, n = 42TR band, n = 42P value
Pre-procedure
IR verapamil, %(86%)(83%)0.77
IR nitroglycerine, %(31%)(45%)0.18
Procedural
Heparin, IU7778 ± 27047825 ± 24500.94
Number of target vessels treated with PCI
1
239391
≥ 3331
001
Target vessels
LM100.98
LAD/Diagonal19220.87
LCx/OM770.96
RCA18120.64
IM020.77
VG020.77
Fluoroscopy times, min15.3 ± 8.415.0 ± 6.90.88
Post-procedure
GP2B3A inhibitor, %1 (2%)0%0.32
ACT ( s )197 ± 38197 ± 470.97
Table 3 Post-procedural outcomes in Safeguard Radial vs TR band groups
VariablesSafeguard radial, n = 42TR band, n = 42P value
Bleeding requiring blood transfusion/surgical intervention0%0%1
Hematoma7%0%0.07
Pain/numbness2%0%0.32
Radial artery occlusion at 24 h2%0%0.32
Radial artery occlusion at 6 wk0%0%1